GLA-SE, a synthetic toll-like receptor 4 agonist, enhances T-cell responses to influenza vaccine in older adults

Journal of Infectious Diseases

Volumn 205, Issue 3, 2012, Pages 466-473

  Behzad, Hayedeh ^a   Huckriede, Anke L W ^c   Haynes, Laura ^d   Gentleman, Beth ^a   Coyle, Krysta ^a   Wilschut, Jan C ^c   Kollmann, Tobias R ^b   Reed, Steven G ^e   McElhaney, Janet E ^a  

^a VANCOUVER COASTAL HEALTH RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^d TRUDEAU INSTITUTE   (United States)

^e Immune Design   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; GLUCOPYRANOSYL LIPID ADJUVANT; GRANZYME B; INFLUENZA VACCINE; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 6; LIPID EMULSION; TOLL LIKE RECEPTOR AGONIST; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RESPONSE; DENDRITIC CELL; DRUG EFFECT; DRUG POTENTIATION; DRUG RESPONSE; EMULSION; HELPER CELL; HUMAN; HUMAN CELL; IMMUNOSTIMULATION; IN VITRO STUDY; INFECTION PREVENTION; INFLUENZA; LYMPHOCYTE ACTIVATION; LYMPHOCYTE FUNCTION; NORMAL HUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; T LYMPHOCYTE SUBPOPULATION; UPREGULATION;

ADJUVANTS, IMMUNOLOGIC; ADULT; AGED; AGED, 80 AND OVER; CELLS, CULTURED; CYTOKINES; DENDRITIC CELLS; HUMANS; INFLUENZA VACCINES; LEUKOCYTES, MONONUCLEAR; TH1 CELLS; TOLL-LIKE RECEPTOR 4; VACCINES, SUBUNIT;

EID: 84855890988     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jir769     Document Type: Article

References (33)

1. Monto AS, Ansaldi F, Aspinall R, et al. Influenza control in the 21st century: Optimizing protection of older adults. Vaccine 2009;27:5043-53.
2. Sambhara S, McElhaney JE. Immunosenescence and influenza vaccine efficacy. Curr Top Microbiol Immunol 2009;333:413-29.
3. Grewe M. Chronological ageing and photoageing of dendritic cells. Clin Exp Dermatol 2001;26:608-12. (Pubitemid 32989586)
4. Haynes L. The effect of aging on cognate function and development of immune memory. Curr Opin Immunol 2005;17:476-9. (Pubitemid 41207949)
5. Zhou X, McElhaney JE. Age-related changes in memory and effector T cells responding to influenza A/H3N2 and pandemic A/H1N1 strains in humans. Vaccine 2011;29:2169-77.
6. Coler RN, Baldwin SL, Shaverdian N, et al. A synthetic adjuvant to enhance and expand immune responses to influenza vaccines. PLoS One 2010;5:e13677.
7. Schreibelt G, Tel J, Sliepen KH, et al. Toll-like receptor expression and function in human dendritic cell subsets: implications for dendritic cell-based anti-cancer immunotherapy. Cancer Immunol Immunother 2010;59:1573-82.
8. Jones SC, Brahmakshatriya V, Huston G, Dibble J, Swain SL. TLR-activated dendritic cells enhance the response of aged naive CD4 T cells via an IL-6-dependent mechanism. J Immunol 2010;185:6783-94.
9. Adams M, Navabi H, Jasani B, et al. Dendritic cell (DC) based therapy for cervical cancer: use of DC pulsed with tumour lysate and matured with a novel synthetic clinically non-toxic double stranded RNA analogue poly [I]:poly [C (12) U] (Ampligen R). Vaccine 2003;21:787-90. (Pubitemid 36091998)
10. Navabi H, Jasani B, Reece A, et al. A clinical grade poly I:C-analogue (Ampligen) promotes optimal DC maturation and Th1-type T cell responses of healthy donors and cancer patients in vitro. Vaccine 2009;27:107-15.
11. Moore A, McCarthy L, Mills KH. The adjuvant combination monophosphoryl lipid A and QS21 switches T cell responses induced with a soluble recombinant HIV protein from Th2 to Th1. Vaccine 1999;17:2517-27. (Pubitemid 29314444)
12. Baldridge JR, McGowan P, Evans JT, et al. Taking a Toll on human disease: Toll-like receptor 4 agonists as vaccine adjuvants and monotherapeutic agents. Expert Opin Biol Ther 2004;4:1129-38. (Pubitemid 38937554)
13. Shahid Z, Kleppinger A, Gentleman B, Falsey AR, McElhaney JE. Clinical and immunologic predictors of influenza illness among vaccinated older adults. Vaccine 2010;28:6145-51.
14. McElhaney JE, Xie D, Hager WD, et al. T cell responses are better correlates of vaccine protection in the elderly. J Immunol 2006;176:6333-9.
15. McElhaney JE, Ewen C, Zhou X, et al. Granzyme B: correlates with protection and enhanced CTL response to influenza vaccination in older adults. Vaccine 2009;27:2418-25.
16. Coler RN, Bertholet S, Shaverdian N, et al. A synthetic adjuvant to enhance and expand immune responses to influenza vaccine. PLoS One 2010;5:e13677.
17. Fox CB, Anderson RC, Dutill TS, Goto Y, Reed SG, Vedvick TS. Monitoring the effects of component structure and source on formulation stability and adjuvant activity of oil-in-water emulsions. Colloids Surf B Biointerfaces 2008;65:98-105.
18. Gijzen K, Liu WM, Visontai I, et al. Standardization and validation of assays determining cellular immune responses against influenza. Vaccine 2010;28:3416-22.
19. Kollmann TR, Crabtree J, Rein-Weston A, et al. Neonatal innate TLR-mediated responses are distinct from those of adults. J Immunol 2009;183:7150-60.
20. Huang CC, Duffy KE, San Mateo LR, Amegadzie BY, Sarisky RT, Mbow ML. A pathway analysis of poly (I:C)-induced global gene expression change in human peripheral blood mononuclear cells. Physiol Genomics 2006;26:125-33. (Pubitemid 44061321)
21. Tesar BM, Walker WE, Unternaehrer J, et al. Murine [corrected] myeloid dendritic cell-dependent toll-like receptor immunity is preserved with aging. Aging Cell 2006;5:473-86. (Pubitemid 44782616)
22. Coler RN, Bertholet S, Moutaftsi M, et al. Development and characterization of synthetic glucopyranosyl lipid adjuvant system as a vaccine adjuvant. PLoS One 2011;6:e16333.
23. Haynes L, Eaton SM, Burns EM, Rincon M, Swain SL. Inflammatory cytokines overcome age-related defects in CD4 T cell responses in vivo. J Immunol 2004;172:5194-9. (Pubitemid 38542015)
24. Skowronski DM, Hottes TS, McElhaney JE, et al. Immuno-epidemiologic correlates of pandemic H1N1 surveillance observations: higher antibody and lower cell-mediated immune responses with advanced age. J Infect Dis 2011;203:158-67.
25. Coler RN, Bertholet S, Moutaftsi M, et al. Development and characterization of synthetic glucopyranosyl lipid adjuvant system as a vaccine adjuvant. PLoS One 2011;6:e16333.
26. Franceschi C, Capri M, Monti D, et al. Inflammaging and antiinflammaging: a systemic perspective on aging and longevity emerged from studies in humans. Mech Ageing Dev 2007;128:92-105. (Pubitemid 46073065)
27. Auray G, Facci MR, van Kessel J, Buchanan R, Babiuk LA, Gerdts V. Differential activation and maturation of two porcine DC populations following TLR ligand stimulation. Mol Immunol 2010;47:2103-11.
28. Makela SM, Strengell M, Pietila TE, Osterlund P, Julkunen I. Multiple signaling pathways contribute to synergistic TLR ligand-dependent cytokine gene expression in human monocyte-derived macrophages and dendritic cells. J Leukoc Biol 2009;85:664-72.
29. Trevejo JM, Marino MW, Philpott N, et al. TNF-alpha-dependent maturation of local dendritic cells is critical for activating the adaptive immune response to virus infection. Proc Natl Acad Sci U S A 2001;98:12162-7. (Pubitemid 32959844)
30. Trinchieri G. Interleukin-12: a cytokine produced by antigen-presenting cells with immunoregulatory functions in the generation of T-helper cells type 1 and cytotoxic lymphocytes. Blood 1994;84:4008-27. (Pubitemid 24371902)
31. Jameson J, Cruz J, Terajima M, Ennis FA. Human CD8+ and CD4+ T lymphocyte memory to influenza A viruses of swine and avian species. J Immunol 1999;162:7578-83. (Pubitemid 29277740)
32. Wang M, Lamberth K, Harndahl M, et al. CTL epitopes for influenza A including the H5N1 bird flu; genome-, pathogen-, and HLA-wide screening. Vaccine 2007;25:2823-31. (Pubitemid 46420615)
33. Agius E, Lacy KE, Vukmanovic-Stejic M, et al. Decreased TNF-alpha synthesis by macrophages restricts cutaneous immunosurveillance by memory CD4+ T cells during aging. J Exp Med 2009;206:1929-40.